StockNews.com initiated coverage on shares of Taro Pharmaceutical Industries (NYSE:TARO - Free Report) in a research note published on Thursday morning. The firm issued a strong-buy rating on the stock.
Separately, HC Wainwright cut shares of Taro Pharmaceutical Industries from a buy rating to a neutral rating and set a $43.00 target price on the stock. in a research note on Thursday, January 18th.
Read Our Latest Analysis on Taro Pharmaceutical Industries
Taro Pharmaceutical Industries Stock Performance
Shares of NYSE:TARO traded up $0.09 on Thursday, hitting $42.13. 29,986 shares of the company were exchanged, compared to its average volume of 50,123. The company's 50 day moving average price is $42.17 and its two-hundred day moving average price is $39.63. Taro Pharmaceutical Industries has a one year low of $23.92 and a one year high of $45.76. The firm has a market capitalization of $1.58 billion, a price-to-earnings ratio of 34.53 and a beta of 0.61.
Taro Pharmaceutical Industries (NYSE:TARO - Get Free Report) last posted its quarterly earnings data on Thursday, January 25th. The company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.30 by $0.26. The company had revenue of $157.15 million for the quarter, compared to the consensus estimate of $154.90 million. Taro Pharmaceutical Industries had a net margin of 7.48% and a return on equity of 3.26%. Research analysts predict that Taro Pharmaceutical Industries will post 1.38 earnings per share for the current year.
Institutional Trading of Taro Pharmaceutical Industries
Large investors have recently added to or reduced their stakes in the company. Harvest Management LLC lifted its position in shares of Taro Pharmaceutical Industries by 3.9% during the fourth quarter. Harvest Management LLC now owns 7,380 shares of the company's stock worth $308,000 after purchasing an additional 274 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in Taro Pharmaceutical Industries by 1.4% in the third quarter. Bank of New York Mellon Corp now owns 22,223 shares of the company's stock valued at $838,000 after buying an additional 307 shares during the period. Legal & General Group Plc increased its stake in Taro Pharmaceutical Industries by 5.3% in the fourth quarter. Legal & General Group Plc now owns 6,732 shares of the company's stock valued at $195,000 after purchasing an additional 339 shares in the last quarter. UBS Group AG increased its stake in Taro Pharmaceutical Industries by 71.6% in the second quarter. UBS Group AG now owns 925 shares of the company's stock valued at $34,000 after purchasing an additional 386 shares in the last quarter. Finally, Swiss National Bank increased its stake in Taro Pharmaceutical Industries by 2.0% in the second quarter. Swiss National Bank now owns 20,900 shares of the company's stock valued at $793,000 after purchasing an additional 400 shares in the last quarter. 91.40% of the stock is owned by institutional investors.
Taro Pharmaceutical Industries Company Profile
(
Get Free Report)
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products.
Featured Stories
Before you consider Taro Pharmaceutical Industries, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Taro Pharmaceutical Industries wasn't on the list.
While Taro Pharmaceutical Industries currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
